’Explosive’ growth in foreign drug testing raises ethical questions
Peek inside any American family's medicine cabinet and you're likely to find a drug that was tested in a foreign country. Pharmaceutical companies have been shifting research overseas for years and the number of foreign trials has skyrocketed. The Department of Health and Human Services reports more than a 2,000% increase in the number of foreign trials for U.S. drugs over the past two decades. In 2008, about 80% of drug applications approved by the Food and Drug Administration contained data from foreign clinical trials. The growth in developing countries and emerging economies in particular has been "explosive" said Arthur Caplan, MD, director of the Center for Bioethics at University of Pennsylvania's Perelman School of Medicine. Caplan explained the appeal of holding clinical trials in developing countries and the ethical issues raised by this research trend.
- Urologists 'Outraged' Over PSA Test Challenge
- New Facebook Page Gathers Stories of Medical Harm
- Luxury Hospital Facilities Put Patient Experience First
- Five Hospitals Share Three Secrets to Improve Knee Surgery Outcomes
- Heartland Health Joins Mayo Clinic Network
- Health Insurance Exchanges Put Defined Benefits to the Test
- Beleaguered Fairview Health CEO to Retire in July
- How Rivals Built an ACO
- Challenging Physicians to Help Improve the ED
- TN Health System Charts Its Own Course

